Halozyme Therapeutics, Inc. (HALO) NASDAQ

68.73

+1.455(+2.16%)

Updated at August 18 02:55PM

Currency In USD

Valuation

Market Cap6.06B
Enterprise Value7.45B
P/E Ratio14.89
PEG Ratio0.91
Price/Sales Ratio6.79
Price/Book Ratio24.93
Enterprise/Revenue8.01
Enterprise/EBITDA11.93

Fiscal Year

Fiscal YearDecember 31, 2024
Most Recent QuarterJune 30, 2025

Profitability

Profit Margin0.47
Operating Margin0.58

Management Effectiveness

Return On Assets0.27
Return On Equity1.37

Income Statement

Revenue1.02B
Revenue/Share9.71
Gross Profit855.91M
EBITDA656.54M
Net Income444.09M
Diluted EPS3.43

Balance Sheet

Total Cash548.18M
Total Cash/Share4.52
Total Debt1.51B
Total Debt/Equity4.54
Current Ratio8.36
Book Value Per Share2.74

Price History

52-Week Change10.74
52-Week High70.51
52-Week Low42.01
Moving Average 50 Days57.07
Moving Average 200 Days56.12

Statistics

Average Volume2.38M
Shares Outstanding116.97M
% Held by Institutions98.71

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A